Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile

• DOI: 10.1128/spectrum.02560-21
• Publication Date: 2022-02-23T21:34:14Z
• Authors: Jeffrey M. Sturek; Tania A. Thomas; James D. Gorham; Chelsea A. Sheppard; Allison H. Raymond; Kristen Petros De...; William B. Harrin...; Andrew J. Barros; Gregory R. Madden; Yosra M. Alkabab; David Y. Lu; Qin Liu; Melinda D. Poulter; Amy J. Mathers; Archana Thakur; Dana L. Schalk; Ewa M. Kubicka; Lawrence G. Lum; Scott K. Heysell
• Keywords: Pandemic; Convalescent plasma; 2019-20 coronavirus outbreak

Transfusion of high-titer CIP to non-critically ill patients early after admission with COVID-19 respiratory disease was associated significantly increased anti-SARS-CoV-2 specific antibodies (compared baseline) and a non-significant reduction in ICU transfer death controls). This prospective phase II trial provides suggestion that the antiviral effects from pandemic may delay progression critical illness patient populations.